%0 Journal Article
%A Romero, Miguel E. jimenez
%A Gallego, Maria Camacho
%A Serrato, Jose c. navarro
%A Sanchez Hurtado, Miguel A.
%A Santotoribio, Jose D.
%T Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
%D 2021
%@ 0250-7005
%U https://hdl.handle.net/10668/25155
%X Background/Aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration resistant prostate cancer (mCPRC), and to identify the survival prognostic factors. Patients and Methods: Patients diagnosed with mCPRC not previously treated with chemotherapy and administered with AA+P were classified into two groups: those with lower and higher survival rates (at 30 months vs. 60 months). Results: A total of 53 patients were studied at the time of mCRPC diagnosis. Patients with the highest survival rate had suffered prostate cancer for >45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 16 months, and had the following tumour marker serum levels: LDH baseline
%K Prostate cancer
%K castration-resistant
%K abiraterone acetate
%K prednisone
%K chemo-naive
%K survival
%K prognostic models
%K Clinical-outcomes
%K Plus prednisone
%K Antigen
%K Men
%K Model
%K Enzalutamide
%K Cou-aa-302
%K Diagnosis
%~